Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters

Database
Language
Document Type
Year range
1.
Sci Rep ; 12(1): 20373, 2022 Nov 27.
Article in English | MEDLINE | ID: covidwho-2133622

ABSTRACT

Immune response induced by COVID-19 vaccine booster against delta and omicron variants was assessed in 65 adults (65-84 years old) early aftesr a first booster dose. An increase in SARS-CoV-2 neutralizing antibodies was shown in individuals not previously infected without evidence of an age-related effect, with lower increase in those infected before a single dose of primary vaccination. Of note, humoral response was observed only starting from the 5th day after the boost.


Subject(s)
COVID-19 , Viral Vaccines , Humans , Aged , Aged, 80 and over , Antibodies, Neutralizing , SARS-CoV-2/genetics , Neutralization Tests , Antibodies, Viral , RNA, Messenger , COVID-19/prevention & control , Vaccination
2.
Int J Infect Dis ; 112: 247-253, 2021 Nov.
Article in English | MEDLINE | ID: covidwho-1654532

ABSTRACT

OBJECTIVES: Few studies have reported clinical COVID-19 sequelae six months (M6) after hospital discharge, but none has studied symptom severity. METHODS: Prevalence and severity of 7 symptoms were estimated until M6 using the self-administered influenza severity scale in COVID-19 hospitalized patients enrolled in the French COVID cohort. Factors associated with severity were assessed by logistic regression. Anxiety, depression and health-related quality of life (HRQL) were also assessed. RESULTS: At M6, among the 324 patients (median age 61 years, 63% men, 19% admitted to intensive care during the acute phase), 187/324 (58%) reported at least one symptom, mostly fatigue (47%) and myalgia (23%). Symptom severity was scored, at most, mild in 125 (67%), moderate in 44 (23%) and severe in 18 (10%). Female gender was the sole factor associated with moderate/severe symptom reporting (OR = 1.98, 95%CI=1.13-3.47). Among the 225 patients with psychological assessment, 24 (11%) had anxiety, 18 (8%) depressive symptoms, and their physical HRQL was significantly poorer than the general population (p=0.0005). CONCLUSION: Even if 58% of patients reported ≥1 symptom at M6, less than 7% rated any symptom as severe. Assessing symptoms severity could be helpful to identify patients requiring appropriate medical care. Women may require special attention.


Subject(s)
COVID-19 , Cohort Studies , Female , Hospitals , Humans , Male , Middle Aged , Prospective Studies , Quality of Life , SARS-CoV-2 , Self Report
SELECTION OF CITATIONS
SEARCH DETAIL